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Abstract 
      By the use of HLA/epitope tetramers, a tool to 
measure the frequency of specific CTL precursors 
independently of their functional state, our group 
demonstrated that melanocyte-specific CTLs are 
present in the peripheral blood of both melanoma and 
vitiligo patients. Notably, however, vitiligo cells were 
capable of lysing HLA-matched melanoma cell lines 
much more efficiently than CTLs obtained from 
melanoma patients. The increased anti-tumor activity 
of vitiligo CTLs was mainly due to their superior TCR
affinity. The possibility that our results might pose the 
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in vitro research basis to the development of new therapies for melanoma, 
such as the genetic transfer of high affinity anti-tumor TCRs from vitiligo 
donors to HLA-matched melanoma patients, is discussed. 
 
Introduction 
 Significant progress in the understanding of the immune biology of 
melanoma has evolved from the identification of melanoma antigens 
recognized by T cells [1-4]. However, although the presence of melanoma-
specific CTLs in cancer patients demonstrate that tumor cells may not 
completely evade immune recognition, the patient’s immune system can only 
rarely counteract tumor growth [5-7]. Vitiligo is a relatively frequent skin 
disease characterized by the presence of depigmented macules and patches as a 
consequence of local melanocyte loss [8]. An unusual facet of vitiligo is its 
relation to melanoma. CTLs directed to self antigens shared by normal 
melanocytes and melanoma cells are found in both conditions and imply a 
breakdown of tolerance [9-14], yet the resulting immune reaction is the 
opposite [reviewed in 15]. In this respect, reactivity to vitiligo melanocytes 
may be regarded as the effective variant of an immune response often 
ineffective in melanoma. These data, together with the resistance of melanoma 
to conventional chemotherapeutic and radiotherapeutic approaches, have made 
the melanoma/vitiligo dichotomy an important model for immunologic 
investigation. 
 The definition of the mechanisms by which tolerance is established to an 
antigen and those by which tolerance can be terminated are crucial for 
understanding the generation of autoimmune responses yet the absence of 
protective immune responses to tumors. Being the cytotoxic response a key 
component of both tumor immunity and autoimmunity, a comparison between 
anti-melanocytic CTLs from vitiligo and melanoma patients can answer the 
question as to whether differences in CTL precursor frequency, their status of 
activation or their affinity for the peptide-MHC complex have a role in 
determining these opposite immune reactions. 
 By the use of HLA/epitope tetramers, a tool to measure the frequency of 
specific CTL precursors independently of their functional state [16], our group 
demonstrated that melanocyte-specific CTLs are present in the peripheral 
blood of both primary melanoma and vitiligo patients [17-20]. Notably, 
however, vitiligo cells are capable of lysing HLA-matched melanoma cell lines 
much more efficiently than CTLs obtained from melanoma patients [17-19]. 
The increased anti-tumor activity of vitiligo CTLs is mainly due to their 
superior TCR affinity. 
 Our results might pose the in vitro research basis to the development of 
new therapies for melanoma, such as the genetic transfer of high affinity anti-
tumor TCRs from vitiligo cells to melanoma peripheral lymphocytes with the 
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aim to redirect their antigen specificity toward a target relevant to anti-tumor 
immunity. 
 
High frequencies of circulating melanocyte-specific CD8+ T 
lymphocytes are found in both melanoma and vitiligo patients 
 Our first aim was to obtain an accurate estimate of the precursor 
frequencies of CTLs specific for three different melanocyte differentiation 
antigens in melanoma and vitiligo patients. We thus synthesized three 
fluorescent HLA-A2 tetramers complexed with both parental and modified 
melanoma peptides from Melan-A/MART1 (peptide A27L), tyrosinase 
(peptide 1-9) and gp100 (peptide 209M). The specificity of each tetramer had 
already been confirmed in our laboratory by staining CTL lines or clones 
specific for HLA-A2 in association with the peptide of interest. The limit of 
detection of each tetramer, determined by titrating known antigen-specific T 
cells into normal PBMC, was established to be 0.04% of CD8+ T cells for 
A2/Melan-A and A2/tyrosinase tetramers, and 0.06% of CD8+
 
T cells for 
A2/gp100. We used these three tetramers to stain PBMC from sixteen HLA-
A2+ melanoma patients and twelve HLA-A2+ vitiligo patients directly ex vivo, 
without any antigen-specific stimulation [17, 18 and unpublished results]. 
Clinical characteristics of the patients are presented in Table I. High numbers 
of both Melan-A/MART1- and tyrosinase-specific cells were detected in the 
majority of patients (Table I and Fig.1). Detection was dependent on the 
expression of HLA-A*0201, as none of several A*0201-negative melanoma 
and vitiligo patients had detectable tetramer+ cells ex vivo [17, 18]. The 
frequency of A2/Melan-A tetramer+ cells varied between 0.02% and 0.35% 
(mean 0.11%) of the total CD8+ population in melanoma and between 0.07% 
and 0.28% (mean 0.14%) of the total CD8+ population in vitiligo; the 
frequency of A2/tyrosinase-positive cells between 0.02% and 0.24% (mean 
0.13%) in melanoma and between 0.10 and 0.22 (mean 0.16%) in vitiligo 
(Table I and Fig. 1). On the contrary, very few gp100-specific CD8+ T cells 
could be observed ex vivo by tetramer staining (Table I), and we demonstrated 
this was due to a low precursor frequency of these cells in both groups of 
patients [17]. 
 These data demonstrated the presence of comparably high frequencies of 
melanocyte-specific CTLs in the peripheral blood of both melanoma and 
vitiligo patients. 
 As a second aim, we assessed whether the melanocyte-specific CTLs 
found in the two diseases had a history of antigen exposure and if they were 
capable of exerting intact cytotoxic activities. The activation status of these 
cells   was   expressed   in   terms   of  naive/effector/memory  component.  We 
observed that all patients contained variable proportions of A2/Melan-A 
tetramer+ lymphocytes displaying an effector/memory phenotype and that their 
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Table 1. 
 
Melanoma 
Patient Sex 
a Melan-A Tyrosinase gp100
ALO F 0.05 _ _
API M 0.11 0.07 0.01
ATO M 0.17 _ _
BBR M 0.11 _ _
EBI F 0.35 _ 0.00
CPA F 0.15 _ _
GCO F 0.10 _ 0.00
GGE M 0.04 _ _
GPE M 0.02 0.02 0.01
IFE M 0.02 0.05 0.02
LCO F 0.08 _ 0.00
OBO M 0.16 0.18 0.00
SCO F 0.10 0.23 0.04
SDB F 0.22 0.24 0.01
SLA M 0.10 0.10 0.01
TBE M 0.05 _ _
Vitiligo 
Patient
Disease Extension (%) Course d
AAN F Hands, arms (5%)           Active 0.12 _ 0.00
ADL M Diffuse (80%)              Stable 0.07 0.14 0.02
CLA F Arms (18%)                  Stable 0.07 0.14 0.04
LPA M Face, arms, legs (45%)                                 Active 0.21 0.19 0.01
MBO F Hands, face (18%)   Stable 0.28 0.21 0.04
PSA F Diffuse (80%)            Stable 0.19 0.20 0.04
RNA F Diffuse (80%)            Stable 0.09 0.13 0.06
RSA M Hands, penis (13%) Stable 0.07 0.10 0.01
SCA M Face, penis, hands, 
arms, legs (30%)
Active 0.17 _ 0.01
SCH F Hands, face (1%)    Stable 0.11 _ 0.00
SRI M Diffuse (80%)                 Active 0.09 0.12 _
TSC F Abdomen, feet (18%)       Stable 0.22 0.22 0.00
I/T1aN0M0
I/T1aN0M0
IV c 
IIA/T3aN0M0
IIA/T2aN0M0
a M, male; F, female.
b Percentage of tetramer + cells relative to total CD8 + T cells.
d The disease course was defined as active vitiligo (newly depigmented lesions during 
the last three months) or stable vitiligo (no recent depigmented or repigmented lesions 
in the three months prior to examination).
I/T1aN0M0
c Spontaneous remission.
IIA/T3N0M0
IB/T2N0M0
IIA/T3N0M0
IIB/T4N0M0
A2-tetramer + cells b
IIA/T3N0M0
IIA/T3N0M0
IB/T2N0M0
Stage
I/T1aN0M0
IIA/T2aN0M0
II/T2bN0M0
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Figure 1. Detection of circulating melanocyte-specific CD8+ T Lymphocytes in 
melanoma and vitiligo patients. Stainings with two different peptide-loaded HLA-
A*0201 tetramers are shown on two melanoma and two vitiligo patients. Cells were 
gated by forward- and side-scatter for lymphocytes. Gated populations are plotted as 
CD8-staining (horizontal axis) versus tetramer-staining (vertical axis). Boxed 
populations, CD8+ tetramer+ cells (frequencies within total CD8+ T cells above each 
box). Upper side, patient identifiers. 
 
number was comparable in melanoma and vitiligo patients (mean 25.7% in 
melanoma versus 23.9% in vitiligo, difference not significant; unpublished 
results). The lytic capacity of tetramer+ cells was analyzed by complementing 
the use of soluble HLA/peptide complexes with intracellular FACS analysis; in 
particular, we assessed if melanocyte-specific cells had intact cytotoxic 
properties through perforin release analyses. The results indicated that 
comparable numbers of tetramer+ cells contained perforin (mean 16% in 
melanoma versus 17% in vitiligo, difference not significant; unpublished 
results). 
 These observations were in agreement with previous literature data 
indicating that Melan-A-specific CTLs from both melanoma and vitiligo 
patients frequently show signs of an in vivo antigen encounter [17, 18, 21, 22] 
and indicate that the activation status of melanocyte-specific CTLs is not a 
distinctive feature of either diseases. 
 
Melan-A/MART1-specific T cells from vitiligo patients are 
characterized from high avidity and tumor-reactivity 
 Avidity of antigen recognition is an important feature of tumor-specific T 
lymphocytes, determining their capability to kill tumor cells. We measured this 
important feature as the ability of the melanocyte-specific cells to respond to 
the stimulation provided by titrated peptide-MHC complexes. As the T cell 
response is a peptide concentration-dependent sigmoidal function, the peptide 
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concentration that elicits a half-maximal response can be considered a measure 
of the functional cell avidity. We assessed the functional avidity of A2/Melan-
A tetramer+ T-cell clones generated from peptide-sensithyzed T cell lines from 
two melanoma (SDB and OBO) and one vitiligo (PSA) patients. Titration 
curves over a wide concentration range (5000 nM to 0.03 nM) of the Melan-A 
analog peptide A27L [23] were generated and clone avidity was defined as the 
concentration of peptide required to obtain half maximal lysis (nM[50%]) at an 
E:T cell ratio of 5:1 in a standard cytotoxicity assay. In the case of melanoma, 
all clones could specifically lyse peptide pulsed target cells, but they 
demonstrated a broad range of avidity, varying between 0.4 and 113 nM (the 
coefficient of variation is 215.2) [18]. Similarly, Melan-A/MART1-specific 
CTL clones were established from the vitiligo patient and their relative avidity 
measured. Interestingly, the relative avidity of all clones turned out to be 
extremely high, with [nM]50% comprised between 0.3 and 11 [17]. 
 Next, we examined whether the melanocyte-specific CTLs isolated from 
both melanoma and vitiligo are capable of exerting tumor reactivity. We 
assessed the lytic activity of CTL clones against HLA-matched melanoma cell 
lines, which present the peptide through endogenous processing pathways. We 
found that tumor reactivity correlated with clone avidity, as only those clones 
exhibiting very high avidity of antigen recognition were capable of efficiently 
killing tumor cells (Fig. 2 for some representative cases) [17, 18]. 
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Figure 2. Tumor-reactivity of Melan-A/MART1-specific CTL clones. T cell clones, 
derived by limiting dilution from Melan-A/MART1-sensityzed cell lines of melanoma 
patients OBO and SDB and of vitiligo patient PSA, were tested in standard 4-h 
chromium release assays for their ability to lyse two different, HLA-matched, 
melanoma cell lines (501 mel and 213 mel). Lysis of T2 cells pulsed with a HLA-
A*0201 restricted, irrelevant peptide (gp100-209M) was performed as control. Points 
are means of triplicates. Shown is one of several experiments done. n, 501 mel; ■, 
213 mel; ▲, T2 + irrelevant peptide. 
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Figure 3. Functional avidity and tumor-reactivity of ex-vivo sorted Melan-A-
specific T cells. (A) Freshly isolated PBMC from one HLA-A2 melanoma patient 
(SCO) and one HLA-A2 vitiligo patient (PSA) were stained with A2/A27L tetramers 
and anti-CD8 mAb and analyzed by flow cytometry. The percentage of tetramer+ cells 
within the CD8+ population is shown. Cells within the gate were FACS sorted using a 
FACSVantage SE. (B) Sorted Melan-A-specific CD8+ T cells, that had been shortly 
expanded in vitro, were tested for their peptide specificity through TCR down-
regulation experiments. HLA-A2+ TAP deficient T2 cells were pulsed with various 
concentrations of Melan-A A27L peptide and added to effector cells at a final E:T ratio 
of 1:5. After 3 h at 37°C, TCR internalization was measured by flow cytometry using 
A2/Melan-A tetramers. The percentage of surface TCR was calculated with a modified 
method [see ref. 19]. (C) Sorted tetramer+ cells, that had been expanded in vitro, were 
assayed for specific lysis against a Melan-A-expressing, HLA-matched melanoma cell 
line (501 mel) in a standard 4-h chromium release assay. T2 cells pulsed with a HLA-
A2 restricted, irrelevant peptide (MAGE-3271-279) were used as negative control. n, 501 
mel; ▲, T2 + irrelevant peptide. 
 
 To perform a direct comparison of whole melanocyte-specific T cell 
populations in the two diseases, freshly isolated PBMC from one melanoma 
(SCO) and one vitiligo (PSA) HLA-A2+ patients were stained with HLA-A2 
tetramers synthesized around the Melan-A A27L analog peptide [23] together 
with an anti-CD8 mAb and isolated by flow cytometry cell sorting [19]. As 
shown in Fig. 3A, the A2/Melan-A tetramer+ T cells constituted 0.12% and 
0.16% of the CD8+ cells, respectively. Sorted cells were analyzed through 
peptide-specific TCR-down-regulation experiments and cytotoxicity assays 
against a HLA-matched melanoma cell line (Fig. 3, B and C). Both 
experiments confirmed the superior avidity and anti-tumor reactivity of Melan-
A-specific T cells from vitiligo. 
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 Overall, these data suggested that Melan-A/MART1-specific CTLs 
isolated from vitiligo patients possessed a higher avidity and exerted a superior 
anti-tumor activity than those from melanoma. 
 
The increased anti-tumor activity of vitiligo CTLs is mainly 
due to their superior TCR affinity 
 TCR downregulation occurs when T cells recognize specific antigen, i.e., 
peptides bound to major histocompatibility complex molecules expressed on 
antigen presenting cells (APCs) [24, 25]. In specific T-APC conjugates TCRs 
are downregulated in an antigen dose- and time-dependent fashion [25] and the 
extent of TCR downregulation (as measured by decreased cell surface staining 
for TCR) is dependent on the concentration and quality of the agonist 
displayed on the APC surface, but is not influenced by costimulatory 
molecules [25-27]. In this respect, the TCR downregulation assay is a good 
indicator of TCR affinity. Recently, we used a tetramer-based TCR 
downregulation assay developed by ourselves to measure the degree of 
peptide-induced response in the whole Melan-A-specific cell fractions of 
melanoma and vitiligo patients [manuscript submitted]. We found a higher 
affinity of T cell receptor in vitiligo cells, as the concentration of peptide 
required for 50% of maximal downregulation was 6-fold lower than in 
melanoma. 
 These results demonstrated that the augmented functional avidity of 
vitiligo CTLs, which results in their increased anti-tumor activity, was mainly 
due to a higher affinity of their T cell receptors. 
 
Strong TCR-α chain conservation in Melan-A-specific cells 
 TCR-α and -β chains are composed of somatically rearranged V, D and J 
germline-encoded gene segments that confer antigen specificity [28]. Recent 
crystallographic analyses revealed that TCR-α has more contacts with peptide 
than TCR-β, suggesting the possibility that peptide recognition predominantly 
relies on TCR-α [29-32]. T cells specific for the self antigen Melan-A/MART1 
[33, 34] possess an exceptionally high precursor frequency in human 
histocompatibility leukocyte antigen-A2 individuals [35]. This provided a 
unique situation for assessment of the structural relationship between TCR and 
peptide/MHC ligand at both the pre- and post-immune levels. Freshly isolated 
PBMC from one HLA-A2 vitiligo (PSA) and one melanoma patient (SCO) 
were stained with HLA-A2 tetramers synthesized around the Melan-A A27L 
peptide [23] together with an anti-CD8 mAb and analyzed by flow cytometry 
[19]. The CD8+ tetramer+ population was isolated by flow cytometry cell 
sorting and cloned by limiting dilution. To analyze the TCR repertoire 
displayed   by  the  CD8+ A2/Melan-A tetramer+ T  cells,  RNA  was  extracted 
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Figure 4  
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Figure 4. Dominant usage of TCRAV2 is a conserved feature of the Melan-A-
specific peripheral repertoire. (A) TCR-α chain amino acid sequences of Melan-A-
specific cell clones from one melanoma and one vitiligo HLA-A2 patients. CDR3α 
junctional amino acid sequences of ex-vivo sorted Melan-A-specific T cell clones are 
shown. Amino acids either partially or completely formed by non-template added 
nucleotides (N nucleotides) are underlined. These sequence data are available from 
GenBank/EMBL/DDBJ under accession no. AY135832-AY135859. (B). PBMC from 7 
HLA-A2 vitiligo patients and 7 HLA-A2 melanoma patients were enriched for CD8+ 
cells with magnetic beads and analyzed by double staining with A2/Melan-A tetramers 
and anti-AV2.1 mAb. Bars represent the total percentages of tetramer+ cells within the 
CD8+ population; black parts represent the percentages of AV2.1+ cells and gray parts 
the percentages of AV2.1- cells within the tetramer+ CD8+ population. Lower panel 
shows the same samples analyzed by double staining with A2/Flu-MA tetramers and 
anti-AV2.1 mAb. 
 
from 30 vitiligo and 21 melanoma clones and cDNA subjected to RT-PCR 
using a panel of AV and BV oligonucleotides covering virtually 100% of the 
TCR-αβ repertoire. In line with previously published data concerning the 
heterogeneity of the Melan-A-specific TCR-β repertoire [35, 36], Melan-A-
specific CD8+ T cells from these patients were found to rearrange many 
distinct BV gene segments [19]. By contrast, all clones except one expressed 
the same rearranged AV gene segment (AV2, 28/28 clones; the AV 
rearrangement of two clones could not be determined) (Fig. 4A). Direct 
sequencing with an internal AC-specific primer was performed to determine 
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the complete TCR-α CDR3 region of the Melan-A-specific clones. The AV2 
segment was always productively rearranged and the CDR3 regions were all 
different, indicative of a large degree of polyclonality in the specific TCR 
repertoire (Fig. 4A). To assess whether the selective use of this AV segment 
was a generalized feature of Melan-A-specific cells, PBMC from 14 HLA-
A2 patients (7 with vitiligo and 7 with melanoma) were analyzed [19]. 
PBMC were enriched in CD8+ cells with magnetic beads and stained with 
A2/Melan-A tetramers in association with an anti-AV2.1 mAb. The high 
percentages of AV2.1-expressing cells in the tetramer+ population of all our 
patients (range 50-87%; mean ± SD, 67% ± 10.9%) was consistent with a 
highly preferential use of AV2 in forming the Melan-A-specific TCR (Fig. 
4B). HLA-A2 tetramers built around the Flu-MA peptide were also used in 
conjunction with the AV2.1 mAb to stain these samples. None of the A2/Flu-
MA tetramer+ cells turned out to be AV2.1+, indicating that preferential 
usage of this AV segment is specifically relevant for recognition of the self 
antigen Melan-A (Fig. 4B). This molecular analysis of many different 
Melan-A-specific T cell populations revealed that a structural constraint is 
imposed on the TCR for engagement with Melan-A peptides presented by 
HLA-A2. 
 In the same work [19], the origin of the AV2+, Melan-A-specific T cells 
was directly investigated by tetramer staining T cells from the human 
thymus. Examination of CD8 single-positive thymocytes indicated that this 
preferential use in forming the Melan-A-specific TCR was mainly imposed 
by intrathymic positive selection. 
 Overall, these data demonstrated a dominant function of TCRAV2 
segment in forming the TCR repertoire specific for the human self antigen 
Melan-A/MART1 and supported the view that antigen recognition is 
mediated predominantly by TCR-α. 
 
The Melan-A-specific peripheral T cell repertoire comprises 
three groups of cells with variable avidity of Ag recognition 
 PSA is a female HLA-A*0201 homozygote patient affected by non-
familial, nonsegmental, patchy vitiligo diffuse on the face, arms, hands, 
thorax, groin, axillae and legs. The disease affects 80% of the patient’s body 
surface and it has been stable for more than ten years. The patient does not 
suffer from any other related autoimmune disease and remained free of 
therapy during the follow-up period relative to our study (three years). 
Freshly isolated PBMC from this patient were stained with A2/Melan-A 
tetramers and anti-CD8 mAb directly ex vivo, without any Ag-specific 
stimulation and analyzed by flow cytometry [20]. The A2/Melan-A tetramer+ 
T cells represented 0.16% of the CD8+ cells at this time point and exhibited a 
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mixed phenotype composed of naive (CD45RA+CD28+, 57%), effector 
(CD45RA+CD28-, 15%) and memory cells (CD45RA-CD45RO+, 24%) (data 
not shown). CD8+ tetramer+ population was isolated by flow cytometry cell 
sorting and sorted cells were immediately cloned by limiting dilution. 29 
clones, all staining positive to the tetramers (not shown), were functionally 
characterized. Avidity of Ag recognition was assessed by titrating both 
Melan-A A27L analogue and Melan-A26-35 natural peptides in a functional 
CTL assay on T2 target cells. Three groups of clones were distinguishable 
according to their functional activity: group 1) clones that specifically lysed 
both Melan-A A27L- and Melan-A26-35-pulsed T2 cells, group 2) clones that 
recognized Melan-A A27L peptide but failed to specifically lyse Melan-A26-
35-pulsed T2 cells, and group 3) clones that failed to significantly recognize 
both Melan-A peptides (Fig. 5). Redirected lysis experiments were 
performed to ascertain functionality of the clones belonging to group 3. Only 
one clone was found to be non-functional (not shown). TCR down-regulation 
upon peptide encounter was found to perfectly correlate with the functional 
avidity of the clones (Fig. 5), supporting the above classification. 
 In that paper [20] we demonstrated, for the first time, that many high 
avidity T cell clones from this patient were capable of specifically lysing 
normal, HLA-matched melanocytes and that many autoreactive clones 
persisted for more than three years in the patient’s peripheral blood. These 
data, together with the skin-homing potential of the clones, directly pointed 
to the in vivo pathogenic role of melanocyte-specific CTL in vitiligo. 
 At variance with the T cell clones we previously isolated from a Melan-
A-sensitized cell line from this vitiligo patient, which homogeneously 
exhibited high avidity of Melan-A recognition [17], ex-vivo isolated 
tetramer+ T cell clones displayed a large heterogeneity in terms of both 
avidity and fine specificity. Clones reacting with the natural Melan-A26-35 
peptide represented only a minority of the total population and were among 
the ones displaying higher avidity of recognition of Melan-A A27L 
analogue-pulsed cells. Surprisingly, a significant proportion of ex vivo sorted 
tetramer+ T cell clones failed to recognize both Melan-A peptides. Possibly, 
these clones exhibited some degree of specificity for Melan-A Ag, sufficient 
to bind A2/Melan-A tetramers, but their functional avidity was too low to be 
detected in a functional assay. Though we cannot formally demonstrate it, we 
believe that these clones represent essentially naive cells that are specific   
for some of the many Melan-A epitope mimics described so far [37, 38] and 
that they do not participate to the anti-melanocyte immune response in      
this patient. This would explain the presence of a conspicuous fraction of 
naive A2/Melan-A tetramer+ cells even in patients with a long-lasting 
disease. 
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Figure 5. Ex-vivo sorted A2/Melan-A tetramer+ T cells from a HLA-A2+ vitiligo 
patient can be classified into three functional groups. Sorted A2/Melan-A tetramer+ 
CD8+ T cells were cloned by limiting dilution immediately after sorting and 29 
independent clones were analyzed. Upper panel, avidity of three representative 
tetramer+ vitiligo clones as measured in a standard 4 h chromium release assay against 
T2 cells pulsed with increasing concentrations of either the natural Melan-A26-35 (■) or 
the analogue Melan-A A27L (n) peptide, at an effector:target (E:T) cell ratio of 5:1. 
Group 1 clones specifically lysed both Melan-A A27L- and Melan-A26-35-pulsed T2 
cells, group 2 clones recognized Melan-A A27L peptide but failed to lyse Melan-A26-35-
pulsed T2 cells, and group 3 clones failed to significantly recognize both Melan-A 
peptides. At the same E:T cell ratio, lysis of empty T2 cells were used as negative 
control (▲). Points are means of triplicates. Data shown represent one of three 
experiments with similar results. In lower panel, clones were tested in TCR down-
regulation experiments. T2 cells were pulsed with increasing concentrations of the 
natural (Melan-A26-35, ■), the analogue (Melan-A A27L, n) or an irrelevant (MAGE-3, 
▲) peptide and added to effector cells to give a final E:T ratio of 1:5. After 1.5-3 h at 
37°C, TCR internalization was measured by flow cytometry using an anti-TCR 
antibody. Figure shows one representative case for each of the three groups. Data 
shown represent one of two experiments with similar results. 
 
 Our data were in perfect agreement with those reported by Dutoit et al. on 
naive A2/Melan-A-reactive populations from normal donors [39] where the 
authors detected the same three functionally distinct groups of tetramer+ clones 
and possibly reflect the fact that the tetramer+ cells of our patient PSA contain 
a significant proportion of naïve cells. These results also suggested that in vitro 
Ag stimulation is the method of choice to select high avidity, self-specific cells 
from patients’ PBMC. 
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Clinical perspectives: Genetic transfer of tumor-specific T cell 
receptors from vitiligo to melanoma 
 Autoimmune conditions stem from a break of tolerance to defined 
autoantigens and this allows for the production of high avidity antigen-
specific responses. If these antigens are also relevant to tumor immunity, 
autoimmune cells can be exploited for tumor intervention. As the antigen 
specificity of T lymphocytes is dictated solely by the T cell receptor (TCR) α 
and β chains, genetic transfer of TCR chains may be an appealing strategy 
with which to impose a desirable tumor-antigen specificity onto recipient T 
cell populations, thus providing a promising tool for immunogene therapy of 
tumors [40-44]. This strategy is limited though, as it is often difficult to 
obtain high affinity, tumor-antigen-specific TCRs from most cancer patients. 
Ideally, model systems where strong and efficient responses against      
tumor antigens are achieved would represent a better source of therapeutic 
cells. 
 We have identified one such model in the melanoma-vitiligo dichotomy. 
From our results, the increased anti-tumor activity of vitiligo CTLs appeared 
to be mainly due to their superior TCR affinity and indeed, a characteristic 
shared by several different models of autoimmunity is the change in the 
repertoire that occurs during the course of disease progression. A way by 
which Ag availability can change the repertoire is through alterations in the 
avidity of the T cells that recognize autoantigens. A number of studies have 
found that, during the course of an immune response to foreign Ag, selection 
occurs in favor of T cells that have high affinity for Ag and that these high 
affinity selected cells are the ones which enter the memory pool [45-48]. It is 
possible that this also occurs in an autoimmune response like vitiligo. 
Features of affinity maturation are increasingly restricted TCR repertoires, 
and average increased avidity [45, 49]. In this respect, the restricted range of 
high avidities displayed by group 1 T cell clones, the preferential use of 
specific AV and BV segments and the selection for conserved CDR3 motifs 
in their β chain [20] suggest that affinity maturation occurred in the Melan-
A/MART-1-specific T cell population during vitiligo development. 
 In this context, it might be interesting to design a TCR transfer approach 
where high affinity TCRs from vitiligo donors will be used to redirect the 
antigen specificity of peripheral lymphocytes from HLA-matched melanoma 
patients. We will address several issues which are crucial to the successful 
use of TCR genes for immunogene therapy, such as preservation of fine 
specificity, preservation of functional avidity and formation of chimeric 
receptors upon TCR transfer. Ultimately, this approach will be relevant to 
learning if protective immune functions can be enhanced for tumor immunity 
without excessive self-destruction. 
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